remirez, I don't agree its the end game for XToll.At this stage...

remirez, I don't agree its the end game for XToll.
At this stage the drug is not effective enough but with further development they may be able to get it to a sufficient efficacy level and there is a possibility it could be used to treat Lupus.
That said I wouldn't get too excited by the results of the treatment of mice using XToll.
Quote from the Lupus data:
"XToll entirely prevented cutaneous lupus. XToll also significantly suppressed nephritis in the kidneys, and significantly prolonged life span"
Trials on mice often fail in humans, but it does show it's possible.

In the NN update:
"XToll is thought to modulate the immune system and bring it back into balance. The Board believes that XToll could potentially become an important therapy for autoimmune and inflammatory diseases, and we continue to explore all opportunities for the commercialisation of this drug candidate," said CBio Chairman, Dr Ralph Craven.

"The company’s largest clinical trial to date completed in Q2 2011 and showed biological activity and signs of clinical effect in patients with moderate to severe RA."

So there is still life left in this Company.
Hopefully they can develop this drug into a success and get Pharma support, for the sake of all you suffering shareholders.
I will look at taking a position if they can do so.